SG/CALL/BRISTOL-MYERS SQUIBB/70/0.1/20.06.25

SG/CALL/BRISTOL-MYERS SQUIBB/70/0.1/20.06.25 Stock

DE000SW7MH19

Real-time Boerse Frankfurt Warrants 05:59:47 2024-07-17 am EDT
0.026 ^EUR	+4.00%

Current month	+4.17%
1 month	-7.41%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart SG/CALL/BRISTOL-MYERS SQUIBB/70/0.1/20.06.25

Latest news about BRISTOL-MYERS SQUIBB COMPANY

ANALYST RECOMMENDATIONS : American Airlines, Chevron, UnitedHealth, Bank of America, Eli Lilly...	05:11am
Goldman Sachs Trims Price Target on Bristol-Myers Squibb to $55 From $56, Buy Rating Maintained	Jul. 16	MT
Transcript : Bristol-Myers Squibb Company Presents at UBS Virtual Targeted Protein Degradation Day, Jul-15-2024 11:00 AM	Jul. 15
UBS Cuts Bristol-Myers Squibb Price Target to $43 From $47, Maintains Neutral Rating	Jul. 12	MT

More news

Quotes 5-day view

Date	Price	Change
24-07-17	0.026	+4.00%
24-07-16	0.025	+19.05%
24-07-15	0.021	-8.70%
24-07-12	0.023	-8.00%
24-07-11	0.025	0.00%

Real-time Boerse Frankfurt Warrants

Last update July 17, 2024 at 05:59 am EDT

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	Société Générale
WKN	SW7MH1
ISIN	DE000SW7MH19
Date issued	2024-03-12
Strike	70 $
Maturity	2025-06-20 (339 Days)
Parity	10 : 1
Emission price	0.16 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	0.18 €
Lowest since issue	0.016 €
Spread	0.01 €
Spread %	27.78%

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company